Evidence map›Paper›PMID 39272836›Full record

ArticleCancers2024

New Insights into the Exosome-Induced Migration of Uveal Melanoma Cells and the Pre-Metastatic Niche Formation in the Liver.

Raquel Ramos, Antònia Vinyals, Rafael Campos-Martin, Eduard Cabré, Joan Josep Bech, Javier Vaquero, Ester Gonzalez-Sanchez, Esther Bertran, Josep Ramon Ferreres, Daniel Lorenzo and 4 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Management of liver metastases from uveal melanoma.The British journal of surgery · 2025
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Raquel RamosTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-3185-0361
Antònia VinyalsTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0003-3925-0050
Rafael Campos-MartinDivision of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, 50937 Cologne, Germany.
Eduard CabréTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Joan Josep BechClinical Proteomics Unit, IDIBELL, 08908 Barcelona, Spain.
Javier VaqueroTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Ester Gonzalez-SanchezTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-9636-9624
Esther BertranTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Josep Ramon FerreresTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0002-2679-3067
Daniel LorenzoOcular Translational Eye Research Unit, Ophthalmology Department, Spanish Ocular Oncology National Referral Center (CSUR), Hospital Universitari de Bellvitge, 08907 Barcelona, Spain.ORCID 0000-0001-7545-7257
Carolina G De La TorreClinical Proteomics Unit, IDIBELL, 08908 Barcelona, Spain.
Isabel FabregatTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.ORCID 0000-0003-0136-8440
Jose Maria CaminalOcular Translational Eye Research Unit, Ophthalmology Department, Spanish Ocular Oncology National Referral Center (CSUR), Hospital Universitari de Bellvitge, 08907 Barcelona, Spain.ORCID 0000-0001-9563-0344
Àngels FabraTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08907 Barcelona, Spain.

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca (2017SGR0188 and 2021SGR00029)Asociación Española Contra el Cáncer (GCB15152978SOEN)Instituto de Salud Carlos III PI15/01461, PI18/1131
6 · The paper itself

Abstract

UM is an aggressive intraocular tumor characterized by high plasticity and a propensity to metastasize in the liver. However, the underlying mechanisms governing liver tropism remain poorly understood. Given the emerging significance of exosomes, we sought to investigate the contribution of UM-derived exosomes to specific steps of the metastatic process. Firstly, we isolated exosomes from UM cells sharing a common genetic background and different metastatic properties. A comparison of protein cargo reveals an overrepresentation of proteins related to cytoskeleton remodeling and actin filament-based movement in exosomes derived from the parental cells that may favor the detachment of cells from the primary site. Secondly, we assessed the role of macrophages in reprogramming the HHSCs by exosomes. The activation of HHSCs triggered a pro-inflammatory and pro-fibrotic environment through cytokine production, upregulation of extracellular matrix molecules, and the activation of signaling pathways. Finally, we found that activated HHSCs promote increased adhesion and migration of UM cells. Our findings shed light on the pivotal role of exosomes in pre-metastatic niche construction in the liver.

Indexed as

amoeboid migrationexosomeshepatic stellate cellsliver metastasismacrophagesmesenchymal migrationuveal melanoma

Identifiers

PMID39272836
PMCPMC11394004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.